Laboratorio Farmaceutico - Public Comps and Valuation Multiples

Laboratorio Farmaceutico Overview

About Laboratorio Farmaceutico

Laboratorio Farmaceutico Erfo SpA operates in the nutraceutical sector. The company specializes in formulating and producing food supplements and natural medicines in different forms such as liquids, powders, granules, tablets, and soft gels. Geographically, the company generates a majority of its revenue from Italy followed by Spain, France, Belgium, and other countries.

Founded

HQ

Employees

Website

erfo.it

Sectors

Food & Beverages

Financials

LTM Revenue $9.7M

LTM EBITDA $2.3M

EV

$14.0M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Laboratorio Farmaceutico Financials

As of August 2025, Laboratorio Farmaceutico reported last 12-month revenue of $9.7M and EBITDA of $2.3M.

In the same period, Laboratorio Farmaceutico achieved $0.7M in LTM net income.

See Laboratorio Farmaceutico valuation multiples based on analyst estimates

Laboratorio Farmaceutico P&L

In the most recent fiscal year, Laboratorio Farmaceutico reported revenue of $7.0M and EBITDA of $1.8M.

Laboratorio Farmaceutico expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Laboratorio Farmaceutico valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$9.7M	XXX	$7.0M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$3.0M	XXX	XXX	XXX
Gross Margin	n/a	XXX	44%	XXX	XXX	XXX
EBITDA	$2.3M	XXX	$1.8M	XXX	XXX	XXX
EBITDA Margin	24%	XXX	26%	XXX	XXX	XXX
EBIT	$1.3M	XXX	$1.1M	XXX	XXX	XXX
EBIT Margin	14%	XXX	15%	XXX	XXX	XXX
Net Profit	$0.7M	XXX	$0.6M	XXX	XXX	XXX
Net Margin	7%	XXX	9%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Laboratorio Farmaceutico including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $9.7M. EBITDA for the last twelve months was $2.3M. In the most recent fiscal year, Laboratorio Farmaceutico achieved $7.0M in revenue and $1.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$9.7M	Analyst estimates available to subscribers	$7.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$3.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	43.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$2.3M	Analyst estimates available to subscribers	$1.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	23.7% EBITDA margin	Analyst estimates available to subscribers	26.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$1.3M	Analyst estimates available to subscribers	$1.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	13.7% EBIT margin	Analyst estimates available to subscribers	15.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$0.7M	Analyst estimates available to subscribers	$0.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	7.4% net profit margin	Analyst estimates available to subscribers	9.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Laboratorio Farmaceutico

This financial data table provides comprehensive performance metrics for Laboratorio Farmaceutico, a company based in Italy. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Laboratorio Farmaceutico generated $9.7M in revenue over the last twelve months.
The company achieved $2.3M in EBITDA over the last twelve months.
Net income over the last twelve months reached $0.7M.

Fiscal Year Performance

In the most recent fiscal year, Laboratorio Farmaceutico reported $7.0M in total revenue.
Fiscal year EBITDA was $1.8M.
The company maintained a gross profit margin of 43.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 26.4%.
Net profit margin reached 9.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Laboratorio Farmaceutico. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Laboratorio Farmaceutico Stock Performance

Laboratorio Farmaceutico has current market cap of EUR 11.9M (or $13.9M), and EV of EUR 12.0M (or $14.0M).

Market Cap Evolution

Laboratorio Farmaceutico Stock Data

As of September 12, 2025, Laboratorio Farmaceutico's stock price is EUR 1 (or $2).

See Laboratorio Farmaceutico trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$14.0M	$13.9M	XXX	XXX	XXX	XXX	$0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Laboratorio Farmaceutico Valuation Multiples

Laboratorio Farmaceutico's trades at 2.0x EV/Revenue multiple, and 7.6x EV/EBITDA.

See valuation multiples for Laboratorio Farmaceutico and 15K+ public comps

Laboratorio Farmaceutico Financial Valuation Multiples

As of September 12, 2025, Laboratorio Farmaceutico has market cap of $13.9M and EV of $14.0M.

Equity research analysts estimate Laboratorio Farmaceutico's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Laboratorio Farmaceutico has a P/E ratio of 19.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$13.9M	XXX	$13.9M	XXX	XXX	XXX
EV (current)	$14.0M	XXX	$14.0M	XXX	XXX	XXX
EV/Revenue	1.4x	XXX	2.0x	XXX	XXX	XXX
EV/EBITDA	6.1x	XXX	7.6x	XXX	XXX	XXX
EV/EBIT	10.6x	XXX	13.0x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	19.5x	XXX	21.5x	XXX	XXX	XXX
EV/FCF	-131.5x	XXX	-80.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Laboratorio Farmaceutico Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Laboratorio Farmaceutico Margins & Growth Rates

Laboratorio Farmaceutico's last 12 month revenue growth is 32%

Laboratorio Farmaceutico's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Laboratorio Farmaceutico's rule of 40 is 67% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Laboratorio Farmaceutico's rule of X is 104% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Laboratorio Farmaceutico and other 15K+ public comps

Laboratorio Farmaceutico Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	32%	XXX	40%	XXX	XXX	XXX
EBITDA Margin	24%	XXX	26%	XXX	XXX	XXX
EBITDA Growth	37%	XXX	17%	XXX	XXX	XXX
Rule of 40	67%	XXX	59%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	104%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	28%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial